Telo Genomics Corp.

OTCPK:TDSG.F Stock Report

Market Cap: US$5.9m

Telo Genomics Management

Management criteria checks 4/4

Telo Genomics' CEO is Sabine Mai, appointed in Dec 2023, has a tenure of 8.25 years. total yearly compensation is CA$30.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 3.77% of the company’s shares, worth $224.18K. The average tenure of the management team and the board of directors is 3.7 years and 4.8 years respectively.

Key information

Sabine Mai

Chief executive officer

CA$30.0k

Total compensation

CEO salary percentage100.0%
CEO tenureless than a year
CEO ownership3.8%
Management average tenure3.7yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sabine Mai's remuneration changed compared to Telo Genomics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$3m

Jun 30 2024CA$30kCA$30k

-CA$3m

Mar 31 2024n/an/a

-CA$3m

Dec 31 2023n/an/a

-CA$3m

Sep 30 2023n/an/a

-CA$3m

Jun 30 2023CA$30kn/a

-CA$3m

Mar 31 2023n/an/a

-CA$3m

Dec 31 2022n/an/a

-CA$2m

Sep 30 2022n/an/a

-CA$2m

Jun 30 2022CA$30kn/a

-CA$2m

Mar 31 2022n/an/a

-CA$2m

Dec 31 2021n/an/a

-CA$2m

Sep 30 2021n/an/a

-CA$1m

Jun 30 2021CA$24kn/a

-CA$1m

Mar 31 2021n/an/a

-CA$1m

Dec 31 2020n/an/a

-CA$953k

Sep 30 2020n/an/a

-CA$1m

Jun 30 2020CA$20kn/a

-CA$1m

Mar 31 2020n/an/a

-CA$1m

Dec 31 2019n/an/a

-CA$1m

Sep 30 2019n/an/a

-CA$634k

Jun 30 2019CA$30kn/a

-CA$1m

Dec 31 2018n/an/a

-CA$3m

Sep 30 2018n/an/a

-CA$4m

Jun 30 2018CA$16kn/a

-CA$5m

Compensation vs Market: Sabine's total compensation ($USD20.81K) is below average for companies of similar size in the US market ($USD650.40K).

Compensation vs Earnings: Sabine's compensation has been consistent with company performance over the past year.

CEO

Sabine Mai

less than a year

Tenure

CA$30,000

Compensation

Dr. Sabine Mai, Ph. D. is Interim Chief Executive Officer at Telo Genomics Corp since December 08, 2023. She is Chair of Clinical & Scientific Advisory Board at Telo Genomics Corp. (formerly known as 3D Si...

Leadership Team

NamePositionTenureCompensationOwnership
Sabine Mai
Founderless than a yearCA$30.00k3.77%
$ 224.2k
Sherif Louis
President & CTO6.3yrsCA$167.37kno data
Christopher Ross
Chief Financial Officer3.7yrsCA$60.00kno data

3.7yrs

Average Tenure

Experienced Management: TDSG.F's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sabine Mai
Founder8.3yrsCA$30.00k3.77%
$ 224.2k
Kenneth Anderson
Member of Clinical & Scientific Advisory Board8.1yrsno datano data
William Meekison
Independent Director4.8yrsCA$18.00k0.040%
$ 2.4k
Ronald McGlennen
Independent Director2.8yrsCA$40.83kno data
Richard Bender
Member of Clinical Advisory Boardno datano datano data
Guido Baechler
Chairman of the Board5.8yrsCA$81.67kno data
Shaji K. Kumar
Member of Clinical Advisory Boardless than a yearno datano data
David Samuel Siegel
Member of Clinical Advisory Boardless than a yearno datano data
Hugh A. Rogers
Independent Director6.3yrsno data1.42%
$ 84.8k
James Berenson
Member of Clinical Advisory Boardless than a yearno datano data
Hans Knecht
Member of Clinical & Scientific Advisory Board8.1yrsno datano data
Ivan Borrello
Member of Clinical Advisory Boardless than a yearno datano data

4.8yrs

Average Tenure

59yo

Average Age

Experienced Board: TDSG.F's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 16:23
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Telo Genomics Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution